CN101137368B - 治疗糖尿病的罗氟司特 - Google Patents

治疗糖尿病的罗氟司特 Download PDF

Info

Publication number
CN101137368B
CN101137368B CN2006800072465A CN200680007246A CN101137368B CN 101137368 B CN101137368 B CN 101137368B CN 2006800072465 A CN2006800072465 A CN 2006800072465A CN 200680007246 A CN200680007246 A CN 200680007246A CN 101137368 B CN101137368 B CN 101137368B
Authority
CN
China
Prior art keywords
roflumilast
pharmaceutically acceptable
oxide
acceptable salt
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800072465A
Other languages
English (en)
Chinese (zh)
Other versions
CN101137368A (zh
Inventor
H·-P·克利
G·哈诺尔
D·豪瑟
B·施米特
D·不雷登布洛克
W·沃斯特
J·肯科维斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Nycomed Asset Management GmbH
Nycomed Germany Holding GmbH
Original Assignee
Nycomed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed GmbH filed Critical Nycomed GmbH
Publication of CN101137368A publication Critical patent/CN101137368A/zh
Application granted granted Critical
Publication of CN101137368B publication Critical patent/CN101137368B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CN2006800072465A 2005-03-08 2006-03-03 治疗糖尿病的罗氟司特 Expired - Fee Related CN101137368B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05101772 2005-03-08
EP05101772.1 2005-03-08
PCT/EP2006/060418 WO2006094933A1 (en) 2005-03-08 2006-03-03 Roflumilast for the treatment of diabetes mellitus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2012100579547A Division CN102600144A (zh) 2005-03-08 2006-03-03 治疗糖尿病的罗氟司特

Publications (2)

Publication Number Publication Date
CN101137368A CN101137368A (zh) 2008-03-05
CN101137368B true CN101137368B (zh) 2012-05-16

Family

ID=34938922

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2006800072465A Expired - Fee Related CN101137368B (zh) 2005-03-08 2006-03-03 治疗糖尿病的罗氟司特
CN2012100579547A Pending CN102600144A (zh) 2005-03-08 2006-03-03 治疗糖尿病的罗氟司特

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2012100579547A Pending CN102600144A (zh) 2005-03-08 2006-03-03 治疗糖尿病的罗氟司特

Country Status (15)

Country Link
US (2) US8017633B2 (enExample)
EP (1) EP1874308A1 (enExample)
JP (2) JP5091106B2 (enExample)
KR (1) KR101302838B1 (enExample)
CN (2) CN101137368B (enExample)
AU (1) AU2006222060B2 (enExample)
BR (1) BRPI0609371A2 (enExample)
CA (1) CA2599376C (enExample)
EA (1) EA015382B1 (enExample)
IL (2) IL185277A (enExample)
MX (1) MX2007010560A (enExample)
NO (1) NO20074943L (enExample)
NZ (1) NZ560269A (enExample)
WO (1) WO2006094933A1 (enExample)
ZA (1) ZA200706294B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003209095A1 (en) 2002-02-11 2003-09-04 Antares Pharma, Inc. Intradermal injector
DK1850892T4 (da) 2005-01-24 2023-06-06 Antares Pharma Inc Forfyldt nål-assisteret sprøjtejetinjektor
US8017633B2 (en) * 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
US8251947B2 (en) 2006-05-03 2012-08-28 Antares Pharma, Inc. Two-stage reconstituting injector
US9144648B2 (en) 2006-05-03 2015-09-29 Antares Pharma, Inc. Injector with adjustable dosing
BRPI0716134A2 (pt) * 2006-09-07 2013-09-17 Nycomed Gmbh tratamento de combinaÇço para diabetes mellitus
US8814834B2 (en) 2008-03-10 2014-08-26 Antares Pharma, Inc. Injector safety device
CN101548972B (zh) * 2008-04-03 2012-10-17 万特制药(海南)有限公司 一种含有瑞格列奈的固体药物组合物
EP3581224A1 (en) 2008-08-05 2019-12-18 Antares Pharma, Inc. Multiple dosage injector
EP2408493B1 (en) 2009-03-20 2024-07-24 Antares Pharma, Inc. Hazardous agent injection system
US9220660B2 (en) 2011-07-15 2015-12-29 Antares Pharma, Inc. Liquid-transfer adapter beveled spike
US8496619B2 (en) 2011-07-15 2013-07-30 Antares Pharma, Inc. Injection device with cammed ram assembly
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
KR20150003179A (ko) 2012-03-06 2015-01-08 안타레스 팔마, 인코퍼레이티드 분리력 특징을 가진 사전충전형 주사기
US9950125B2 (en) 2012-04-06 2018-04-24 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
WO2013169804A1 (en) 2012-05-07 2013-11-14 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
US9744302B2 (en) 2013-02-11 2017-08-29 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
WO2014124860A1 (en) 2013-02-14 2014-08-21 Boehringer Ingelheim International Gmbh Specific pde4b-inhibitors for the treatment of diabetes mellitus
EP3572108A1 (en) 2013-03-11 2019-11-27 Antares Pharma, Inc. Dosage injector with pinion system
WO2014165136A1 (en) 2013-03-12 2014-10-09 Antares Pharma, Inc. Constant volume prefilled syringes and kits thereof
EP3165224A1 (en) * 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017182873A2 (en) 2016-04-19 2017-10-26 Ureka Sarl Peptide-oligourea foldamer compounds and methods of their use
GB202306663D0 (en) * 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020002191A1 (en) * 2000-05-25 2002-01-03 Richard Friesen Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor
WO2004016596A1 (en) * 2002-08-19 2004-02-26 Glenmark Pharmaceuticals Limited Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
US20050049258A1 (en) * 2001-01-31 2005-03-03 Pfizer Inc Ether derivatives useful as inhibitors of PDE4 isozymes

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
JPS5869812A (ja) 1981-10-22 1983-04-26 Chugai Pharmaceut Co Ltd 血糖降下剤
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
NZ225447A (en) 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9215633D0 (en) 1992-07-23 1992-09-09 Smithkline Beecham Plc Novel treatment
MX9304571A (es) 1992-07-28 1994-05-31 Rhone Poulenc Rorer Ltd Compuestos fanilicos ligados a un arilo o heteroarilo mediante un radical alifatico o un atomo heterogeneo que contiene un grupo eslabonador.
AU682156B2 (en) 1992-10-15 1997-09-25 Dana-Farber Cancer Institute, Inc. Treatment of insulin resistance in obesity linked type II diabetes using antagonists to TNF-alpha function
KR100331255B1 (ko) 1993-07-02 2002-10-25 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도
CN1043993C (zh) 1994-08-29 1999-07-07 山之内制药株式会社 萘啶衍生物及其医药组合物
KR100454781B1 (ko) 1996-01-31 2005-04-08 알타나 파마 아게 신규한페난트리딘
DE19617864A1 (de) 1996-04-23 1997-10-30 Schering Ag Neue chirale Phenyldihydrofuranone
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
ATE273996T1 (de) 1997-09-12 2004-09-15 Pharis Biotec Gmbh Zusammensetzung zur therapie von diabetes mellitus und fettsucht
SE9801992D0 (sv) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
AU774868B2 (en) 1999-01-15 2004-07-08 Takeda Gmbh Phenylphenanthridines with PDE-IV inhibiting activity
ES2241571T3 (es) 1999-01-15 2005-11-01 Altana Pharma Ag N-oxidos de fenantrinida con actividad inhividora de pde-iv.
US7323496B2 (en) * 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
WO2001035979A2 (en) 1999-11-13 2001-05-25 Icos Corporation Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
KR100729289B1 (ko) 1999-12-08 2007-06-18 아스카 세이야쿠 가부시키가이샤 신규한 1,8-나프티리딘-2(1ｈ)-온 유도체
WO2001068621A1 (en) 2000-03-13 2001-09-20 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclohexene derivatives useful as antagonists of the motilin receptor
CA2404226A1 (en) 2000-03-23 2001-09-27 Takeda Chemical Industries, Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
KR100586765B1 (ko) 2000-08-11 2006-06-08 오노 야꾸힝 고교 가부시키가이샤 피페리딘 유도체 및 그 유도체를 유효 성분으로 하는 약제
CA2419033A1 (en) 2000-08-11 2002-02-21 Earl Michael Gibbs Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
WO2002074726A2 (en) 2001-01-22 2002-09-26 Memory Pharmaceuticals Corporation Aniline derivatives useful as phosphodiesterase 4 inhibitors
CA2436551A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
EA200300836A1 (ru) 2001-02-15 2004-02-26 Алтана Фарма Аг Производные фталазинон-пиперидина в качестве ингибиторов pde4
HUP0600103A2 (en) * 2001-03-02 2006-06-28 Bristol Myers Squibb Co Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
DE10150517A1 (de) 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
US20030181461A1 (en) 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
HUE039709T2 (hu) * 2002-05-28 2019-01-28 Astrazeneca Ab Helyileg alkalmazandó gyógyászati készítmény
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
WO2004098595A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
WO2004098597A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and shuil-1r ii
WO2004098596A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising roflumilast and il-1 trap
WO2004098598A1 (en) 2003-05-12 2004-11-18 Altana Pharma Ag COMPOSITION COMPRISING ROFLUMILAST AND A TNFα ANTAGONIST
BRPI0410326A (pt) * 2003-05-22 2006-05-23 Altana Pharma Ag composição compreendendo um inibidor pde4 e inibidor pde5
WO2005020926A2 (en) 2003-08-28 2005-03-10 Pharmacia Corporation Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors
JP2007504201A (ja) 2003-09-05 2007-03-01 アルタナ　ファルマ　アクチエンゲゼルシャフト 真性糖尿病の治療のためのｐｄｅ４阻害剤の使用
WO2005041864A2 (en) 2003-10-21 2005-05-12 Pharmacia Corporation Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method
CN101027560A (zh) 2004-04-13 2007-08-29 艾尼纳制药公司 用于治疗高血糖症和相关病症的人类g蛋白偶合受体及其调节物
US8017633B2 (en) * 2005-03-08 2011-09-13 Nycomed Gmbh Roflumilast for the treatment of diabetes mellitus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020002191A1 (en) * 2000-05-25 2002-01-03 Richard Friesen Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitor
US20050049258A1 (en) * 2001-01-31 2005-03-03 Pfizer Inc Ether derivatives useful as inhibitors of PDE4 isozymes
WO2004016596A1 (en) * 2002-08-19 2004-02-26 Glenmark Pharmaceuticals Limited Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
US 20020002191 A1,说明书第0015和0049段.

Also Published As

Publication number Publication date
MX2007010560A (es) 2008-02-21
NZ560269A (en) 2010-12-24
WO2006094933A1 (en) 2006-09-14
CN101137368A (zh) 2008-03-05
KR101302838B1 (ko) 2013-09-03
IL185277A0 (en) 2008-02-09
NO20074943L (no) 2007-10-01
CA2599376C (en) 2014-05-13
CN102600144A (zh) 2012-07-25
JP2012188448A (ja) 2012-10-04
BRPI0609371A2 (pt) 2010-03-30
ZA200706294B (en) 2008-09-25
EA015382B1 (ru) 2011-08-30
HK1116077A1 (en) 2008-12-19
CA2599376A1 (en) 2006-09-14
JP2008532974A (ja) 2008-08-21
IL221006A0 (en) 2012-08-30
KR20070111539A (ko) 2007-11-21
AU2006222060A1 (en) 2006-09-14
US20110269750A1 (en) 2011-11-03
US8541456B2 (en) 2013-09-24
JP5611275B2 (ja) 2014-10-22
IL185277A (en) 2013-08-29
US20080214625A1 (en) 2008-09-04
EA200701845A1 (ru) 2008-02-28
AU2006222060B2 (en) 2011-09-01
JP5091106B2 (ja) 2012-12-05
US8017633B2 (en) 2011-09-13
EP1874308A1 (en) 2008-01-09

Similar Documents

Publication Publication Date Title
CN101137368B (zh) 治疗糖尿病的罗氟司特
KR20090047546A (ko) 당뇨병을 위한 조합 치료
CN1960735B (zh) 药物组合在治疗胰岛素抗性中的应用
Doupis et al. DPP4 inhibitors: a new approach in diabetes treatment
Hossain et al. Current antidiabetic drugs: review of their efficacy and safety
CN101969927A (zh) 预防glp-1不良影响的方法
AU2025201814A1 (en) Therapeutic uses of GLP1R agonists
CN104968341B (zh) Glp1r激动剂和二甲双胍的组合及其在制备治疗2型糖尿病和其他障碍的药物中的用途
EP4487909A2 (en) Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
Kadhe et al. Advances in drug delivery of oral hypoglycemic agents
CN114306601A (zh) 一种l型氨基酸转运蛋白抑制剂或拮抗剂有效干预糖尿病的方法
CN113559088A (zh) 一种含二甲双胍和西格列汀的复方降糖药物制剂
HK1116077B (en) Roflumilast for the treatment of diabetes mellitus
HK1171663A (en) Roflumilast for treatment of diabeties mellitus
HK40042198A (en) Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
HK1137345A (en) Combination treatment for diabetes mellitus
Gallwitz Sitagliptin and Metformin in Fixed Dose Combination: The Emerging Evidence of its Therapeutic Impact in Type 2 Diabetes
HK1210424B (zh) Glp1r 激动剂和二甲双胍的组合及其在制备治疗 2 型糖尿病和其他障碍的药物中的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1116077

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1116077

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: TAKEDA GMBH

Free format text: FORMER NAME: NYCOMED INC.

CP01 Change in the name or title of a patent holder

Address after: Konstanz

Patentee after: TAKEDA GmbH

Address before: Konstanz

Patentee before: Nycomed GmbH

ASS Succession or assignment of patent right

Owner name: NYCOMED GERMANY HOLDING GMBH

Free format text: FORMER OWNER: NYCOMED ASSET MANAGEMENT GMBH

Effective date: 20150619

Owner name: NYCOMED ASSET MANAGEMENT GMBH

Free format text: FORMER OWNER: TAKEDA GMBH

Effective date: 20150619

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: TAKEDA GMBH

Free format text: FORMER NAME: NYCOMED GERMANY HOLDING GMBH

CP01 Change in the name or title of a patent holder

Address after: Konstanz

Patentee after: TAKEDA GmbH

Address before: Konstanz

Patentee before: Nycomed Germany holding LLC

TR01 Transfer of patent right

Effective date of registration: 20150619

Address after: Konstanz

Patentee after: Nycomed Germany holding LLC

Address before: Konstanz

Patentee before: Nycomed asset management LLC

Effective date of registration: 20150619

Address after: Konstanz

Patentee after: Nycomed asset management LLC

Address before: Konstanz

Patentee before: TAKEDA GmbH

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120516

Termination date: 20160303

CF01 Termination of patent right due to non-payment of annual fee